A Model-Based Cost-Effectiveness Analysis of Abrocitinib Compared with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: A UK Healthcare Perspective
- DOI
- 10.1007/s41669-026-00693-4
- Published
- 2026-10-28
- Container
- PharmacoEconomics - Open
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s41669-026-00693-4,
title = {A Model-Based Cost-Effectiveness Analysis of Abrocitinib Compared with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: A UK Healthcare Perspective},
author = {Gulraj S. Matharu and Boglarka Mikudina and Karim Amer and Iulia Dunnett and Fionn Woodcock and Zenas Z. N. Yiu},
year = {2026},
journal = {PharmacoEconomics - Open},
doi = {10.1007/s41669-026-00693-4},
url = {https://doi.org/10.1007/s41669-026-00693-4}
}RIS
TY - JOUR TI - A Model-Based Cost-Effectiveness Analysis of Abrocitinib Compared with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: A UK Healthcare Perspective AU - Gulraj S. Matharu AU - Boglarka Mikudina AU - Karim Amer AU - Iulia Dunnett AU - Fionn Woodcock AU - Zenas Z. N. Yiu PY - 2026 JO - PharmacoEconomics - Open DO - 10.1007/s41669-026-00693-4 UR - https://doi.org/10.1007/s41669-026-00693-4 ER -
APA
Matharu, G. S., Mikudina, B., Amer, K., Dunnett, I., Woodcock, F., & Yiu, Z. Z. N. (2026). A Model-Based Cost-Effectiveness Analysis of Abrocitinib Compared with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: A UK Healthcare Perspective. PharmacoEconomics - Open. https://doi.org/10.1007/s41669-026-00693-4
Source records
- crossref · retrieved 2026-11-09T09:48:37.443Z